Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.69 |
| ▸ | PRMT5 | O14744 | 7/20 | 0.49 |
| ▸ | HTR2A | P28223 | 5/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29780341 | 1.00 | HTR2C (0.69) | HTR2CPRMT5HTR2AMTNR1AMTNR1B | |
| SCHEMBL23927895 | 1.00 | HTR2C (0.69) | HTR2CPRMT5HTR2AMTNR1AMTNR1B | |
| SCHEMBL23956071 | 1.00 | HTR2C (0.69) | HTR2CPRMT5HTR2AMTNR1AMTNR1B | |
| SCHEMBL25236285 | 0.92 | HTR2C (0.59) | HTR2CPRMT5HTR2AMTNR1AMTNR1B | |
| Fumaric Acid SCHEMBL27125871 | 0.89 | HTR2C (0.56) | HTR2CPRMT5HTR2AMTNR1AMTNR1B | |
| Fumaric Acid SCHEMBL30729586 | 0.89 | HTR2C (0.56) | HTR2CPRMT5HTR2AMTNR1AMTNR1B | |
| Fumaric Acid SCHEMBL25201003 | 0.89 | HTR2C (0.56) | HTR2CPRMT5HTR2AMTNR1AMTNR1B | |
| SCHEMBL23956079 | 0.85 | HTR2C (0.51) | HTR2CPRMT5HTR2A | |
| SCHEMBL23956076 | 0.85 | HTR2C (0.51) | HTR2CPRMT5HTR2A | |
| SCHEMBL22930056 | 0.84 | HTR2C (0.77) | HTR2CPRMT5HTR2AMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435036-B2 | Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-n,n-dimethylpropan-2-amine | TERRAN BIOSCIENCES INC. (US) | 2025-10-07 | — | — | US | claimed |
| US-12319652-B2 | Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-N,N-dimethylpropan-2-amine | TERRAN BIOSCIENCES INC. (US) | 2025-06-03 | — | — | US | claimed |
| US-20250002456-A1 | SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE | TERRAN BIOSCIENCES INC. | 2025-01-02 | — | — | US | claimed |
| US-20240034718-A1 | SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE | TERRAN BIOSCIENCES INC. | 2024-02-01 | — | — | US | claimed |
| US-20240002337-A1 | SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE | TERRAN BIOSCIENCES INC (US) | 2024-01-04 | — | — | US | claimed |
| WO-2023091974-A2 | SALT AND SOLID FORMS OF (R)-1-(5-METHOXY-1 H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE | TERRAN BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | claimed |
| US-20260138948-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | TERRAN BIOSCIENCES INC (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260078090-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | TERRAN BIOSCIENCES INC. | 2026-03-19 | — | — | US | disclosed |
| US-20260060979-A1 | METHOD FOR IMPROVING NEUROPLASTICITY | ALTO NEUROSCIENCE INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12435036-B2 | Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-n,n-dimethylpropan-2-amine | TERRAN BIOSCIENCES INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-12319652-B2 | Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-N,N-dimethylpropan-2-amine | TERRAN BIOSCIENCES INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-12319652-B2 | Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-N,N-dimethylpropan-2-amine | TERRAN BIOSCIENCES INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20250002456-A1 | SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE | TERRAN BIOSCIENCES INC. | 2025-01-02 | — | — | US | disclosed |
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES INC (US) | 2023-05-25 | — | — | US | disclosed |
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES INC (US) | 2023-05-25 | — | — | US | disclosed |
| WO-2023091974-A2 | SALT AND SOLID FORMS OF (R)-1-(5-METHOXY-1 H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE | TERRAN BIOSCIENCES, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023077127-A2 | N-SUBSTITUTED INDOLES | TERRAN BIOSCIENCES, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2022081631-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | disclosed |
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA CORPORATION | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078090-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | HTR1D, TPH1, HTR3D | HTR2C 5/4885PRMT5 575/4885HTR2A 13/4885 |
| US-20260138948-A1 | N-SUBSTITUTED INDOLES AS 5-HYDROXYTRYPTAMINE (5-HT) SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS | HTR1D, HTR2C, TPH1 | HTR2C 2/4885PRMT5 946/4885HTR2A 14/4885 |
| US-11254640-B2 | N-substituted indoles and other heterocycles for treating brain disorders | TPH2, AANAT, HTR2C | HTR2C 3/4885PRMT5 796/4885HTR2A 5/4885 |
| US-12435036-B2 | Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-n,n-dimethylpropan-2-amine | SLC6A4, GRIN2D, SLC1A2 | HTR2C 10/4885PRMT5 119/4885HTR2A 13/4885 |
| US-20240002337-A1 | SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE | SLC6A4, GRIN2D, SLC1A2 | HTR2C 10/4885PRMT5 119/4885HTR2A 13/4885 |
| US-12319652-B2 | Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-N,N-dimethylpropan-2-amine | SLC6A4, GRIN2D, SLC1A2 | HTR2C 10/4885PRMT5 119/4885HTR2A 13/4885 |
| US-20260060979-A1 | METHOD FOR IMPROVING NEUROPLASTICITY | NTRK2, BDNF, GRIN2A | HTR2C 39/4885PRMT5 3028/4885HTR2A 13/4885 |
| US-20230159456-A1 | N-SUBSTITUTED INDOLES | TPH2, TPH1, AANAT | HTR2C 11/4885PRMT5 661/4885HTR2A 13/4885 |
| US-20240034718-A1 | SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE | SLC6A4, GRIN2D, SLC1A2 | HTR2C 10/4885PRMT5 119/4885HTR2A 13/4885 |
| US-20250002456-A1 | SALTS AND SOLID FORMS OF (R)-1-(5-METHOXY-1H-INDOL-1-YL)-N,N-DIMETHYLPROPAN-2-AMINE | SLC6A4, GRIN2D, SLC1A2 | HTR2C 10/4885PRMT5 119/4885HTR2A 13/4885 |
| US-20210332012-A1 | N-SUBSTITUTED INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | TPH2, AANAT, HTR2C | HTR2C 3/4885PRMT5 796/4885HTR2A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.